elevidys - Search News

News

Roche Pauses Commercial and Clinical Use of Elevidys

The Wall Street Journal on MSN · 13h

Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

MarketWatch · 9h

Sarepta Shares Dive on Second Fatal Liver Failure Tied to Elevidys

Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular dystrophy treatment Elevidys. Shares were trading around $20.61. The stock is down 70% on the year.

Seeking Alpha · 7h

Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an analysis of SRPT stock now.

2hon MSN

Sarepta shares crash as second patient dies after receiving its gene therapy

By Bhanvi Satija and Christy Santhosh (Reuters) -Shares of Sarepta Therapeutics slumped as much as 49.4% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who ...

3hon MSN

Health Care Roundup: Market Talk

Find insight on Sarepta Therapeutics, CSPC Pharmaceutical, Regis Healthcare and more in the latest Market Talks covering the ...

Sarepta reports second patient death after treatment with Duchenne gene therapy

Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...

10h

Sarepta plunges, U.S. Steel rises and other movers

Sarepta Therapeutics shares plunged 36% after the company reported a second case of acute liver failure resulting in death from taking Elevidys, which is a gene therapy for patients with Duchenne ...